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Objectives This study investigated the clinical significance of plasma pentraxin 3 (PTX3) levels in patients with heart failure
with normal ejection fraction (HFNEF) and whether PTX3 is produced from coronary circulation.
Background Pentraxin 3 is a novel inflammatory marker and a member of pentraxin superfamily including C-reactive protein
(CRP). The relationship between inflammatory markers and HFNEF remains unclear.
Methods We measured peripheral blood levels of PTX3, high-sensitivity CRP, tumor necrosis factor-alpha, and
interleukin-6 in 323 patients comprising 82 HFNEF, 70 heart failure (HF) with reduced EF, and 171 non-HF pa-
tients. Levels of PTX3 were also measured at the aortic root and the coronary sinus in 75 patients.
Results The levels of PTX3, tumor necrosis factor-alpha, and interleukin-6, but not high-sensitivity CRP, were significantly
higher in HFNEF patients than in non-HF patients. Multivariate logistic regression analysis identified only high levels of
PTX3 as the independent inflammatory marker correlated with the presence of HFNEF in patients with normal left
ventricular (LV) EF (odds ratio [OR]: 1.49, 95% confidence interval [CI]: 1.11 to 1.98, p  0.01) and with the presence
of left ventricular diastolic dysfunction (LVDD) in non-HF patients (OR: 1.23, 95% CI: 1.02 to 1.50, p  0.05). Levels of
PTX3 at the coronary sinus were significantly higher than at the aortic root in HFNEF patients (p  0.05) and in
non-HF patients with LVDD (p  0.01), but not different in non-HF patients without LVDD (p  0.33).
Conclusions Pentraxin 3 is significantly elevated in HFNEF patients and produced in the coronary circulation in patients with LVDD.
Pentraxin 3, but not high-sensitivity CRP, is an independent inflammatory marker correlated with the presence of
LVDD and HFNEF. (The Clinical Significance of Plasma Pentraxin 3 levels for Patients with Diastolic Heart Failure;
UMIN000002170) (J Am Coll Cardiol 2011;57:861–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.018Heart failure (HF) results from cardiac overload or injury as
well as from a complex interplay among genetic, neurohor-
monal, and inflammatory factors. Biomarkers such as those
for inflammation and neurohormones provide important
information about the pathogenesis, risk stratification, di-
agnosis, and monitoring therapy of HF (1). Inflammatory
markers are closely associated with the worst functional
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PTX3 Correlated With LVDD and HFNEF February 15, 2011:861–9Pentraxin 3 was also implicated as
a predictor of adverse clinical out-
comes in patients with HF (4).
Thus, there is considerable interest
in PTX3 as a more useful and
immediate inflammatory marker
in cardiovascular medicine.
There are 2 types of HF: heart
failure with reduced ejection frac-
tion (HFREF) and heart failure
with normal ejection fraction
(HFNEF). However, the relation-
ship between levels of inflamma-
tory markers and HFNEF remains
to be identified. The aims of the
present study, therefore, were to
determine the clinical significance
of plasma PTX3 levels for HF-
NEF in patients with normal left
ventricular ejection fraction
(LVEF). We also investigated
the correlation between inflam-
matory biomarkers and left
ventricular diastolic dysfunc-
tion (LVDD) among non-HF
patients. Furthermore, we in-
vestigated whether PTX3 could
be produced from a heart with
LVDD.
Methods
Study subjects and protocol. We screened 181 HF pa-
tients with New York Heart Association functional class II
to IV who were referred to Kumamoto University Hospital,
Kumamoto, Japan, from January to December 2008. In each
patient, echocardiography was performed. We finally ana-
lyzed 82 HFNEF and 70 HFREF patients (Fig. 1). This
study also enrolled 171 control subjects without HF
(non-HF patients). Venous blood samples were obtained at
stable and fasting condition to measure levels of serum
high-sensitivity CRP (hsCRP), plasma PTX3, tumor ne-
crosis factor-alpha (TNF-alpha), interleukin-6 (IL-6),
B-type natriuretic peptide (BNP), and other biochemical
markers. Pentraxin 3 was measured using a high-sensitivity
enzyme-linked immunosorbent assay system (Perseus Pro-
teomics, Tokyo, Japan). An expanded methods section is
available in the Online Appendix.
The study was approved by the ethics review committee
of our institution and a signed informed consent was
obtained from each patient before participation. This study
was registered at the University Hospital Medical Informa-
tion Network protocol registration system.
Statistical analysis. Normally distributed results were ex-
pressed as mean  SD. The values of PTX3, hsCRP,
Abbreviations
and Acronyms
BMI  body mass index
BNP  B-type natriuretic
peptide
E/e=  the mitral early
diastolic peak flow velocity
to tissue Doppler early
mitral annular diastolic
velocity
eGFR  estimated
glomerular filtration rate
HF  heart failure
HFNEF  heart failure with
normal ejection fraction
HFREF  heart failure with
reduced ejection fraction
hsCRP  high-sensitivity
C-reactive protein
IL  interleukin
LVDD  left ventricular
diastolic dysfunction
LVEF  left ventricular
ejection fraction
LVMI  left ventricular
mass index
PTX3  pentraxin 3
TNF  tumor necrosis factorTNF-alpha, IL-6, BNP, the mitral early diastolic peak flowvelocity to tissue Doppler early mitral annular diastolic
velocity (E/e=), and left ventricular mass index (LVMI) were
not normally distributed and expressed as the median value
(interquartile range). Statistical analyses are detailed in the
Online Appendix.
Results
Study sample characteristics. Table 1 details the clinical
characteristics of all study subjects. The patients with
HFNEF were older on average than non-HF and HFREF
patients. The levels of estimated glomerular filtration rate
(eGFR) were significantly lower in patients with HFNEF
than in non-HF patients, although the levels of LVEF were
not significantly different between these 2 groups. The levels
of PTX3, TNF-alpha, IL-6, and BNP were significantly
elevated in patients with HFNEF and HFREF compared
with those in non-HF patients. However, hsCRP levels
were significantly elevated only in patients with HFREF,
but not in patients with HFNEF (p  0.14), compared
with non-HF patients.
The levels of PTX3 and BNP increased significantly as
New York Heart Association functional class increased.
Although the levels of hsCRP were significantly higher in
severe HF patients, they were not significantly different in New
York Heart Association functional classes (Online Fig. 1).
Simple linear regression analysis revealed a significant pos-
itive correlation between levels of ln(PTX3) and ln(BNP)
(r  0.472, p  0.001) and significant positive correlation
between levels of ln(PTX3) and ln(hsCRP) (r  0.230,
p  0.001).
Clinical markers correlating with the presence of HFNEF
in patients with normal LVEF. Multivariate linear regres-
sion analysis revealed that the levels of ln(PTX3) indepen-
dently correlated with values of ln(E/e=) among inflamma-
tory markers (beta  0.297, p  0.05, model R2  0.213)
and adjusted age, sex, body mass index (BMI), eGFR,
hypertension, and diabetes (beta  0.157, p  0.05, model
R2  0.289) in patients with normal LVEF. However, the
evels of ln(PTX3) did not significantly correlate with
VEF, the parameter of LV systolic dysfunction (r  0.05,
 0.43). Table 2 details the univariate and multivariate
ogistic regression analyses to identify clinical markers for
he presence of HFNEF among patients with normal
VEF, excluding the parameters in diagnostic criteria:
NP, E/e=, and LVMI. The levels of PTX3, hsCRP, and
NF-alpha, as well as age and eGFR were significantly
orrelated with the presence of HFNEF by the univariate
ogistic regression analysis. In the multivariate logistic re-
ression analysis, PTX3 significantly and independently
orrelated with the presence of HFNEF (odds ratio [OR]:
.49, 95% confidence interval [CI]: 1.11 to 1.98, p  0.01).
This model was reliable (p 0.23 by the Hosmer-Lemeshow
test). In the forced entry models, PTX3, but not hsCRP, was
significantly correlated with the presence of HFNEF among
patients with normal LVEF (OR: 1.47, 95% CI: 1.25 to 1.73,
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February 15, 2011:861–9 PTX3 Correlated With LVDD and HFNEFp  0.001) independent of age, sex, eGFR, hypertension, and
diabetes. This model was reliable (p  0.63 by the Hosmer-
Lemeshow test).
Relationship between PTX3 and LVDD in non-HF
patients. Table 3 details the clinical characteristics of
non-HF patients with or without LVDD. The non-HF
patients with LVDD were older on average than non-HF
patients without LVDD. The levels of PTX3, BMI, and waist
circumference were significantly higher and angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker use
and hypertension were significantly dominant, whereas eGFR
was significantly lower in non-HF patients with LVDD than
those without LVDD. However, the levels of hsCRP, TNF-
alpha, IL-6, BNP, and LVEF were not significantly different
between the 2 groups. In the non-HF population, multivariate
linear regression analysis revealed that the levels of ln(PTX3)
independently correlated with values of ln(E/e=) among in-
ammatory markers (beta  0.291, p  0.05, model R2 
0.148) and adjusted age, sex, BMI, eGFR, hypertension,
diabetes, and BNP (beta  0.147, p  0.05, model R2 
.289). However, the levels of ln(PTX3) did not significantly
orrelate with values of LVEF (r  0.110, p  0.14). We
nvestigated logistic regression analysis of markers to correlate
ith the presence of LVDD in non-HF patients, excluding the
Figure 1 Flow Chart Showing the Enrollment Protocol
Flow chart showing the protocol used for enrollment of heart failure (HF) patients w
without left ventricular diastolic dysfunction (LVDD). BNP  B-type natriuretic pept
annular diastolic velocity; HFNEF  heart failure with normal ejection fraction; HFR
tricular ejection fraction; LVMI  left ventricular mass index.arameters in diagnostic criteria, E/e=, and LVMI. The uni- Pariate logistic regression analysis identified levels of PTX3,
ge, BMI, waist circumference, eGFR, and hypertension, but
ot hsCRP (p  0.62), TNF-alpha (p  0.44), IL-6 (p 
.62), and BNP (p  0.55), as significant markers of the
resence of LVDD. In the multivariate logistic regression
nalysis, PTX3 was the independent marker correlated with
he presence of LVDD among non-HF patients (OR: 1.23,
5% CI: 1.02 to 1.50, p  0.05), independent of age, sex,
MI, eGFR, and hypertension. This model was reliable (p 
.70 by the Hosmer-Lemeshow test).
he presence of HFNEF in patients with LVDD and
ormal LVEF. Among patients with LVDD and normal
VEF (Fig. 1), the levels of PTX3, BNP, TNF-alpha,
L-6, E/e=, and LVMI were significantly higher, and
eta-blockers and diuretics were significantly more used,
hereas eGFR was significantly lower in patients with
FNEF than in non-HF patients with LVDD. How-
ver, hsCRP levels (p  0.20), LVEF (p  0.26), and age
p  0.19) were not significantly different between the 2
roups. Table 4 presents the univariate and multivariate
ogistic regression analyses of markers to correlate with
he presence of HFNEF in patients with LVDD and
ormal LVEF, excluding BNP as the diagnostic criteria
f HF. In the multivariate logistic regression analysis,
rmal ejection fraction and reduced ejection fraction and non–HF patients with or
e=  the mitral early diastolic peak flow velocity to tissue Doppler early mitral
heart failure with reduced ejection fraction; LV  left ventricular; LVEF  left ven-ith no
ide; E/
EF TX3 was the significant and independent marker cor-
t
h eukin;
N
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PTX3 Correlated With LVDD and HFNEF February 15, 2011:861–9related with the presence of HFNEF among patients
with LVDD and normal LVEF (OR: 1.54, 95% CI: 1.08
to 2.18, p  0.05). This model was reliable (p  0.54 by
the Hosmer-Lemeshow test). In the forced entry models,
PTX3, but not hsCRP, was significantly correlated with
the presence of HFNEF among patients with LVDD and
normal LVEF (OR: 1.40, 95% CI: 1.19 to 1.65, p 0.001)
independent of age, sex, eGFR, hypertension, and diabetes.
This model was reliable (p  0.67 by the Hosmer-
Lemeshow test).
Production of PTX3 in the coronary circulation. In 75
consecutive patients who received coronary angiography, we ex-
amined the levels of PTX3 at the coronary sinus and the aortic
Clinical CharacteristicsTable 1 Clinical Characteristics
Non-HF Patients
(n  171)
All
Age, yrs 66.5 11.2
Sex, male/female 97/74
NYHA functional class (II/III/IV)
Body mass index, kg/m2 24.4 6.2
Metabolic syndrome 80 (46.8%) 6
Waist circumference, cm 87.7 9.1
Current smoking 32 (18.7%) 2
Hypertension 116 (67.8%) 9
Diabetes mellitus 64 (37.4%) 5
Glucose, mg/dl 100.4 26.1
Hemoglobin A1c, % 5.9 1.1
CAD 94 (55.0%) 7
Atrial fibrillation 9 (5.3%) 1
Biochemical markers, mg/dl
Total cholesterol 178.5 27.9
HDL cholesterol 54.8 15.0
Triglycerides 117.6 60.7
LDL cholesterol 103.6 24.9
Estimated GFR, ml/min/1.73 m2 69.5 17.8
Inflammatory markers
PTX3, ng/ml 2.18 (1.51–2.90) 3.2
hsCRP, mg/l 0.70 (0.30–1.33) 1.0
TNF-alpha, pg/ml 1.01 (0.05–2.25) 1.6
IL-6, pg/ml 1.24 (0.65–2.39) 3.8
BNP, pg/ml 26.9 (13.2–50.4) 149
Echocardiography
LVEF, % 65.7 5.1
E/e= 11.0 (9.0–13.8) 13
LV mass index, g/m2 143.7 (124.4–160.2) 192
Medications
Beta-blockers 33 (19.4%) 7
ACE-Is or ARBs 72 (42.4%) 9
Calcium-channel blockers 108 (63.5%) 6
Statins 71 (41.8%) 6
Aspirin 90 (52.9%) 7
Diuretics 7 (4.1%) 7
Data are mean  SD, n (%), or median and (interquartile range). *p  0.01 versus non-HF; †p 
ACE-I angiotensin converting enzyme inhibitor; ARB angiotensin II receptor blocker; BNP
o tissue Doppler early mitral annular diastolic velocity; GFR  glomerular filtration rate; HDL  h
eart failure reduced ejection fraction; hsCRP  high-sensitivity C-reactive protein; IL  interl
YHA  New York Heart Association; PTX3  pentraxin 3; TNF  tumor necrosis factor.root. Levels of PTX3 at the coronary sinus were significantlyelevated compared with those at the aortic root in non-HF
patients with LVDD, but were not different in those without
LVDD (Figs. 2A and 2B). In HF patients, the levels of PTX3 at
the coronary sinus were significantly elevated compared with
those at the aortic root in HFNEF or HFREF patients
(Figs. 2C and 2D). The transcardiac gradient of PTX3
(PTX3  coronary sinus – aortic root) in patients with
HFNEF and HFREF, and non-HF patients with LVDD
were significantly higher than in non-HF patients without
LVDD (Fig. 3A). Furthermore, the simple linear regression
analysis revealed a significant positive correlation between
the peripheral levels of ln(PTX3) and the amount of PTX3
production in coronary circulation (r  0.288, p  0.01)
ts With HF
152)
HFNEF
(n  82)
HFREF
(n  70)
 12.2 71.2 10.2*† 65.5 13.6
/55 59/33 48/22
50/24 52/23/7 † 26/27/17
 3.9 24.0 3.7 23.5 4.1
.8%) 39 (50.6%) 26 (38.2%)
 10.7 89.9 10.0‡ 85.6 11.1
.8%) 11 (13.4%) 10 (14.3%)
.8%) 59 (72.0%)‡ 38 (54.3%)
.5%) 37 (45.1%)‡ 20 (28.6%)
 28.2 102.7 28.5 97.2 27.8
 1.0 5.8 1.0 5.9 1.0
.0%) 44 (53.7%) 32 (45.7%)
.2%) 8 (9.8%) 9 (12.9%)
 31.7 173.7 27.9 174.9 35.9
 13.1§ 51.8 13.9‡ 47.3 11.8§
 54.3 114.1 51.8 117.1 57.3
 25.1 99.9 22.0 106.4 27.9
 21.6§ 61.6 21.2* 56.3 21.9§
0–4.55)§ 3.26 (2.36–4.35)‡§ 3.56 (2.20–6.28)§
0–2.25)§ 0.90 (0.40–1.60)‡ 1.15 (0.60–3.30)§
2–3.21) 1.64 (0.68–2.88) 1.73 (0.95–3.64) 
3–7.92)§ 2.45 (1.15–3.96)*† 5.55(2.65–9.41)§
.0–371.2)§ 94.5 (34.8–232.2)†§ 286.5 (98.4–760.2)§
 17.0§ 64.6 7.2† 35.1 9.8§
.2–17.8)§ 13.9 (10.9–16.1)§ 13.9 (11.5–19.7)§
3.2–265.2)§ 158.7 (139.6–194.8)†§ 249.9 (203.5–322.2)§
.3%)* 35 (45.5%) 40 (61.5%)§
.5%)§ 45 (54.9%)‡ 53 (75.7%)§
.4%)* 51 (62.2%)† 18 (25.7%)§
.1%) 40 (48.7%)‡ 21 (30.0%)
.0%) 48 (58.5%) 31 (44.3%)
.7%)§ 19 (23.2%)† 52 (74.3%)§
versus HFREF; ‡p  0.05 versus HFREF; §p  0.001 versus non-HF; p  0.05 vs. non-HF.
natriuretic peptide; CAD coronary artery disease; E/e=mitral early diastolic peak flow velocity
sity lipoprotein; HF  heart failure; HFNEF  heart failure with normal ejection fraction; HFREF 
LDL  low-density lipoprotein; LV  left ventricular; LVEF  left ventricular ejection fraction;Patien
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Logistic Regression Analysis of Clinical Factors for the Presence of HFNEF Among Patients With Normal LVEFTable 2 Logistic Regression Analysis of Clinical Factors for the Presence of HFNEF Among Patients With Normal LVEF
Forced Models
Univariate Multivariate Model 1 Model 2 Model 3
Factor OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Age, yrs 1.04 (1.01–1.07) 0.01 0.99 (0.94–1.06) 0.98 1.02 (0.99–1.05) 0.25 1.03 (1.00–1.06) 0.05 1.02 (0.99–1.05) 0.21
Sex, male 1.15 (0.67–1.96) 0.62 Not selected 1.11 (0.60–2.03) 0.74 1.11 (0.62–1.97) 0.72 1.10 (0.60–2.02) 0.76
Body mass index, kg/m2 0.98 (0.93–1.04) 0.55 Not selected
Metabolic syndrome, yes 1.12 (0.65–1.92) 0.69 Not selected
Waist circumference, cm 1.02 (0.99–1.05) 0.11 Not selected
Current smoking 0.67 (0.32–1.40) 0.29 Not selected
Hypertension, yes 1.23 (0.69–2.19) 0.49 Not selected 1.19 (0.63–2.27) 0.59 1.02 (0.55–1.89) 0.96 1.14 (0.59–2.17) 0.70
Diabetes mellitus, yes 1.36 (0.80–2.33) 0.26 Not selected 1.16 (0.63–2.15) 0.63 1.13 (0.63–2.02) 0.69 1.12 (0.61–2.08) 0.72
Glucose, mg/dl 1.00 (0.99–1.01) 0.53 Not selected
Hemoglobin A1c, % 0.99 (0.77–1.28) 0.93 Not selected
CAD, yes 0.94 (0.55–1.59) 0.81 Not selected
Atrial fibrillation, yes 1.93 (0.72–5.21) 0.19 Not selected
Total cholesterol, mg/dl 0.99 (0.98–1.01) 0.21 Not selected
HDL cholesterol, mg/dl 0.99 (0.97–1.00) 0.13 Not selected
Triglycerides, mg/dl 1.00 (0.99–1.01) 0.66 Not selected
LDL cholesterol, mg/dl 0.99 (0.98–1.01) 0.25 Not selected
Estimated GFR, ml/min/1.73 m2 0.98 (0.96–0.99) 0.01 0.99 (0.95–1.02) 0.42 0.99 (0.97–1.01) 0.19 0.99 (0.97–1.01) 0.13 0.99 (0.97–1.01) 0.26
ln(PTX 3), 0.1 1.54 (1.32–1.80) 0.001 1.49 (1.11–1.98) 0.01 1.49 (1.27–1.76) 0.001 1.47 (1.25–1.73) 0.001
ln(hsCRP), 0.1 1.06 (1.01–1.12) 0.05 1.08 (0.97–1.20) 0.17 1.05 (0.99–1.12) 0.09 1.04 (0.97–1.10) 0.28
ln(TNF-alpha), 0.1 1.11 (1.02–1.21) 0.05 1.09 (0.98–1.20) 0.10
ln(IL-6), 0.1 1.06 (0.96–1.13) 0.26 Not selected
LVEF, % 0.97 (0.92–1.01) 0.15 Not selected
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
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PTX3 Correlated With LVDD and HFNEF February 15, 2011:861–9In contrast, the levels of hsCRP were not significantly
different between levels of the coronary sinus and the aortic
root in all groups (data not shown).
Discussion
In this study, we identified the presence of significantly
elevated levels of PTX3, but not hsCRP, in HFNEF patients
compared with non-HF patients. The levels of PTX3, but not
hsCRP, TNF-alpha, and IL-6, significantly correlated with
values of E/e=, which reflected LVDD. The elevated levels of
PTX3, but not hsCRP, TNF-alpha, and IL-6, were signifi-
cantly and independently correlated with the presence of
HFNEF among patients with normal LVEF and even among
patients with LVDD and normal LVEF.
Inflammatory activation is important in the pathogenesis
Clinical Characteristics of Non-HF Patients WithTable 3 Clinical Characteristics of Non-HF P
With LVD
(n  118
Age, yrs 68.7 1
Sex, male/female 67/51
Body mass index, kg/m2 25.4 3
Metabolic syndrome 60 (50.8%)
Waist circumference, cm 88.8 8
Current smoking 19 (16.1%)
Hypertension 90 (76.3%)
Diabetes mellitus 48 (40.7%)
Glucose, mg/dl 101.8 2
Hemoglobin A1c, % 6.0 1
CAD 69 (59.0%)
Atrial fibrillation 5 (4.2%)
Biochemical markers, mg/dl
Total cholesterol 177.4 2
HDL cholesterol 54.5 1
Triglycerides 113.7 5
LDL cholesterol 103.3 2
eGFR, ml/min/1.73 m2 67.4 1
Inflammatory markers
PTX3, ng/ml 2.28 (1.63–3
hsCRP, mg/l 0.65 (0.30–1
TNF-alpha, pg/ml 1.05 (0.14–2
IL-6, pg/ml 1.26 (0.67–2
BNP, pg/ml 28.6 (12.7–5
Echocardiography
LVEF, % 65.2 5
E/e= 12.3 (10.0–1
LV mass index, g/m2 151.7 (139.7–
Medications
Beta-blockers 24 (20.3%)
ACE-Is or ARBs 58 (49.2%)
Calcium-channel blockers 78 (66.1%)
Statins 51 (43.2%)
Aspirin 66 (56.0%)
Diuretics 6 (5.1%)
Data are mean  SD, n (%), or median and (interquartile range).
LVDD  left ventricular diastolic dysfunction; other abbreviations aof HF and in adverse prognoses in these patients. Theestablished inflammatory marker, hsCRP, is an independent
predictor of morbidity and mortality in patients with HF
(5). The novel inflammatory marker, PTX3, was recently
implicated as a predictor of adverse clinical outcomes in
patients with HF (4). However, in these studies, LVEF in
patients with HF was generally lower than 50%. Previous
studies also identified elevated N-terminal proBNP and
BNP as strong independent predictors of clinical events in
patients with HFNEF (6), and BNP was found to distin-
guish patients with HFNEF from those with LVDD (7).
However, the relationship between inflammatory markers
and HFNEF remained unclear. Williams et al. (8) showed
that elevated CRP levels predicted hospitalization for HF
patients, although this association between CRP and HF
events was no longer significant after adjustment for the
ithout LVDDts With or Without LVDD
Patients (n  171)
Without LVDD
(n  53) p Value
61.7 10.9 0.001
30/23 0.99
23.2 3.2 0.05
20 (38.5%) 0.13
85.2 9.5 0.05
13 (24.5%) 0.21
26 (49.1%) 0.001
16 (30.2%) 0.23
97.1 20.0 0.27
5.6 0.8 0.07
25 (47.2%) 0.18
4 (7.5%) 0.46
180.8 26.7 0.45
55.4 16.2 0.72
123.6 77.5 0.17
104.2 25.0 0.83
74.2 18.7 0.05
1.99 (1.35–2.65) 0.05
0.70 (0.30–1.10) 0.50
0.98 (0.01–1.70) 0.27
1.18 (0.89–1.84) 0.56
26.3 (14.3–41.1) 0.50
66.7 5.3 0.18
9.0 (6.7–10.7) 0.001
) 121.1 (110.7–135.4) 0.001
9 (17.0%) 0.68
14 (26.4%) 0.01
30 (56.6%) 0.23
20 (37.7%) 0.51
24 (45.3%) 0.19
1 (1.9%) 0.44
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D
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7.0
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172.7presence of LVDD. The present study similarly revealed
Logistic Regression Analysis of the Factors for the Presence of HFNEF Among Patients With LVDD and Normal LVEFTable 4 Logistic Regression Analysis of the Factors for the Presence of HFNEF Among Patients With LVDD and Normal LVEF
Forced Models
Univariate Multivariate Model 1 Model 2 Model 3
Factor OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Age, yrs 1.02 (0.99–1.05) 0.19 Not selected 1.01 (0.97–1.04) 0.88 1.01 (0.98–1.05) 0.37 1.01 (0.97–1.04) 0.82
Sex, male 1.21 (0.68–2.14) 0.52 Not selected 1.17 (0.62–2.18) 0.64 1.14 (0.62–2.08) 0.67 1.16 (0.62–2.19) 0.64
Body mass index, kg/m2 0.95 (0.89–1.03) 0.25 Not selected
Metabolic syndrome, yes 0.75 (0.42–1.34) 0.33 Not selected
Waist circumference, cm 1.01 (0.98–1.04) 0.63 Not selected
Current smoking 0.81 (0.36–1.80) 0.60 Not selected
Hypertension, yes 0.88 (0.46–1.65) 0.68 Not selected 0.85 (0.42–1.71) 0.65 0.73 (0.37–1.43) 0.35 0.81 (0.40–1.64) 0.56
Diabetes mellitus, yes 1.12 (0.63–1.97) 0.70 Not selected 1.06 (0.55–2.01) 0.87 1.02 (0.55–1.90) 0.94 1.01 (0.53–1.94) 0.97
Glucose, mg/dl 1.00 (0.99–1.01) 0.97 Not selected
Hemoglobin A1c, % 0.91 (0.69–1.21) 0.52 Not selected
CAD, yes 0.67 (0.35–1.10) 0.10 Not selected
Atrial fibrillation, yes 2.44 (0.77–7.75) 0.13 Not selected
Total cholesterol, mg/dl 0.99 (0.99–1.01) 0.67 Not selected
HDL cholesterol, mg/dl 0.99 (0.97–1.01) 0.42 Not selected
Triglycerides, mg/dl 1.00 (0.99–1.01) 0.81 Not selected
LDL cholesterol, mg/dl 0.99 (0.98–1.01) 0.63 Not selected
Estimated GFR, ml/min/1.73 m2 0.98 (0.97–0.99) 0.05 0.98 (0.94–1.02) 0.31 0.99 (0.97–1.01) 0.28 0.99 (0.97–1.01) 0.23 0.99 (0.97–1.01) 0.39
ln(PTX3), 0.1 1.45 (1.23–1.70) 0.001 1.54 (1.08–2.18) 0.05 1.42 (1.21–1.68) 0.001 1.40 (1.19–1.65) 0.001
ln(hsCRP), 0.1 1.05 (0.99–1.12) 0.10 Not selected 1.05 (0.98–1.11) 0.15 1.03 (0.97–1.10) 0.34
ln(TNF-alpha), 0.1 1.12 (1.01–1.23) 0.05 1.07 (0.96–1.19) 0.24
ln(IL-6), 0.1 1.07 (0.96–1.19) 0.22 Not selected
LVEF, % 0.97 (0.93–1.02) 0.25 Not selected
ln(E/e=), 0.1 1.23 (1.02–1.62) 0.05 1.56 (0.91–2.66) 0.11
ln(LV mass index), 0.1 1.51 (1.09–2.09) 0.05 1.06 (0.56–2.02) 0.85
Abbreviations as in Tables 1 and 2.
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PTX3 Correlated With LVDD and HFNEF February 15, 2011:861–9that hsCRP was not significantly correlated with the pres-
ence of HFNEF. In contrast, PTX3 was shown to be a
significantly independent inflammatory marker of the pres-
ence of HFNEF.
Importantly, this study also identified that PTX3 was an
independent marker correlated with the presence of LVDD
among non-HF patients, independent of age, sex, BMI,
eGFR, and hypertension, and was produced in the coronary
circulation in not only HFNEF patients but also non-HF
patients with LVDD. The amount of PTX3 production in
coronary circulation indicated significant positive correla-
tion with the peripheral levels of PTX3. Small but signifi-
cant differences in PTX3 levels between the aortic root and
the coronary sinus might in part contribute to the increased
levels of PTX3 in peripheral circulation in patients with
LVDD. However, the pathogenetic role of the elevated
PTX3 in LVDD and HF, either as an inducer, suppressor,
Figure 2 PTX3 Levels at the Coronary Sinus and the Aortic Roo
The levels of pentraxin 3 at the coronary sinus were significantly elevated compare
those without LVDD (n  16) (A). In HFNEF (n  11) (C) and HFREF patients (n 
vated compared with those at the aortic root. Abbreviations as in Figure 1.or mere marker, remains unclear. PTX3 was recently im-plicated in a cardioprotective role in mice models of acute
myocardial infarction (9) and has an atheroprotective effect
in apolipoprotein E-knockout mice (10). These studies
suggested that PTX3 might exert its protective properties
on the cardiovascular system through modulating the im-
munoinflammatory balance. Therefore, the elevated PTX3
would possibly play a compensatory cardioprotective role at
the activated inflammatory condition. However, we only
found that PTX3 levels were significantly correlated with
the presence of HFNEF and that PTX3 is a useful inflam-
matory marker, but not an inducer or suppressor, in patients
with HFNEF in the present study. Further studies might be
required to determine the detailed pathological roles of
PTX3 in HFNEF and LVDD.
Study limitations. The present study has certain limita-
tions. The non-HF patients were not randomly selected
from the general population and the values of certain
those at the aortic root in non-HF patients with LVDD (n  32) (B), but not in
D), the levels of pentraxin 3 (PTX3) at the coronary sinus were significantly ele-t
d with
16) (parameters such as blood pressure and lipid profile were
f869JACC Vol. 57, No. 7, 2011 Matsubara et al.
February 15, 2011:861–9 PTX3 Correlated With LVDD and HFNEFprobably influenced to an extent by medications. In addi-
tion, the study investigated only a relatively small number of
patients in a single center. Despite these limitations, how-
ever, this study provided the first evidence for a role of
PTX3 in HFNEF and LVDD. Further in vivo and in vitro
experiments will be needed to determine the mechanisms of
increased PTX3 production in HFNEF and LVDD. A
multicenter trial with a large-scale study population is now
warranted to further examine the role and clinical signifi-
Figure 3 Production of PTX3 in Coronary Circulation
(A) The transcardiac gradient of PTX3 (coronary sinus – aortic root) in patients
with HFREF and HFNEF, as well as non-HF patients with LVDD were significantly
higher than in non-HF patients without LVDD (p  0.05). (B) The simple linear
regression analysis revealed a positive correlation between the peripheral lev-
els of ln(PTX3) and the amount of PTX3 production in coronary circulation (n 
75, r  0.288, p  0.01). PTX3  transcardiac gradient of pentraxin 3; other
abbreviations as in Figures 1 and 2.cance of PTX3 in HFNEF and LVDD.Conclusions
PTX3 is produced in the coronary circulation in HFNEF
patients and in non-HF patients with LVDD and is
significantly elevated in patients with HFNEF. PTX3 could
be a significant inflammatory marker in patients with
HFNEF.
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